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Abstract: The aim of our study was to investigate the dynamics of the alterations of soluble human leukocyte
antigen-G (sHLA-G) concentrations in sera of healthy non-pregnant women, as well as healthy pregnant wom-
en and patients with pre-eclampsia. Thirty five patients with pre-eclampsia, 52 healthy pregnant women, and
24 healthy non-pregnant women were included in the study. Sera concentrations of sHLA-G protein were deter-
mined using the immunoenzymatic ELISA method. Statistical analysis was performed using ANOVA and Mann–
–Whitney U tests. The concentrations of sHLA-G protein in sera of pregnant women in the first, as well as the
second and third, trimesters of normal pregnancy were significantly higher in comparison with healthy non-
pregnant women. The sera concentrations of sHLA-G in pregnant women in the second trimester of pregnancy
were significantly higher compared to the first and third trimesters. The concentrations of sHLA-G in sera of
patients with pre-eclampsia were significantly lower than in pregnant women in the third trimester of physiolog-
ical pregnancy. The results of our study suggest that normal physiological pregnancy is associated with elevated
sera concentrations of sHLA-G molecule. The increased concentrations of sHLA-G molecule in mid-gestation
could suggest a role for the protein in the second phase of a physiological invasion of extravillous cytotropho-
blast to spiral arteries. Furthermore, the results could suggest a role for the decreased sera concentrations of
sHLA-G in the pathogenesis of pre-eclampsia. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 2, 286–291)
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Introduction
Pre-eclampsia (PE) is a common obstetric syndrome
affecting 5–10% of pregnant women. It is the leading
cause of maternal and fetal morbidity and mortality
in developed countries. Pre-eclampsia is mostly diag-
nosed in first pregnancies, and indeed the risk of the
disorder in a second pregnancy is significantly reduced
when in the first pregnancy normal values of blood
pressure have been noted [1, 2].
Although the symptoms of pre-eclampsia appear
in the third trimester of pregnancy, it is generally ac-
cepted that the underlying pathologic changes occur
much earlier in the placenta and placental bed [3]. It
has been proposed that the activation of cell-mediat-
ed immunity may play a role in the etiology of pre-
eclampsia. Many alterations in the adaptive immune
system have been described which could contribute
to the development of this syndrome [4–6]. During
the normal course of pregnancy, the process of im-
munomodulation increases continuously, but it falls
in pre-eclampsia [7–9].
Human leukocyte antigen-G (HLA-G) is a non-
classical major histocompatibility complex (MHC)
class Ib molecule that is expressed primarily during
pregnancy at the maternal-fetal interface. It has mul-
tiple immunoregulatory properties. We can distin-
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guish membrane-bound HLA-G and soluble HLA-G
(sHLA-G) isoforms. Both isoforms are synthesized
by trophoblast cells as well as by fetal cells. The sHLA-G
isoform circulates in maternal blood. Its main func-
tion in physiological conditions is to protect fetal tis-
sues from the maternal NK cell activity, and to estab-
lish immune tolerance at the maternal-fetal interface
[10–12]. Alternative splicing of the HLA-G gene re-
sults in seven different transcriptional isoforms, of
which four encode membrane-bound products, and
the other three encode soluble proteins [10, 11]. The
proteins HLA-G1, HLA-G2, HLA-G3 and HLA-G4
are bound to cell surfaces, while HLA-G5, HLA-G6
and HLA-G7 are soluble isoforms [11, 12]. A soluble
form of HLA-G protein derived from an alternative-
ly spliced form of mRNA may participate in the vas-
cular remodeling of maternal spiral arteries during
pregnancy through the interaction with CD160 [13].
The main isoforms of HLA-G present in serum are
sHLA-G1 and sHLA-G5 which are generated by shed-
ding or proteolytic cleavage of the membrane bound
isoforms and by secretion of soluble isoforms, respec-
tively. It is abundant in the maternal circulation dur-
ing pregnancy. They are present not only on cell sur-
faces, but also in maternal serum, as well as in amni-
otic fluid. They have also been detected in endothe-
lial cells of fetal vessels in the chorionic villi. Moreover,
HLA-G proteins have been found in thymus and fetal
liver and on interferon-g-stimulated blood monocytes [13].
It remains uncertain whether tolerance to HLA-G de-
velops during fetal life [12]. It has also been shown that
the attenuated expressions of HLA-G protein on ex-
travillous trophoblast cells were strongly associated
with recurrent pregnancy losses or embryo transfer
failures after in vitro fertilization and with pre-eclamp-
sia [12, 16]. The sHLA-G molecules may be able to
block the alloreactive maternal cytotoxic T-cell re-
sponse via T-cell receptor binding. Therefore, HLA-G
protein has a cardinal immune role in several aspects
of reproduction including fertility (implantation), gy-
necology (abortions) and obstetrics (abnormal preg-
nancies, e.g. PE) [14, 15, 18, 19].
The aim of our study was to investigate the dy-
namics of the alterations of sHLA-G concentrations
in sera of healthy non-pregnant women, as well as
healthy pregnant women in the first, second and third
trimesters of physiological pregnancy. Furthermore,
the aim of the study was to test the hypothesis that
sHLA-G concentrations are decreased in sera of pa-
tients with pre-eclampsia.
Material and methods
Patients. The pregnant patients participating in the study
were admitted to the Department of Obstetrics and Perina-
tology of the Medical University of Lublin. The study pop-
ulation included 35 patients with pregnancy complicated by
pre-eclampsia. The diagnosis of pre-eclampsia was made
according to the classification criteria of the American Col-
lege of Obstetricians and Gynecologists. Patients with the
following symptoms: elevated blood pressure > 140/90 mm Hg
and with proteinuria — 300 mg or more per 24 hours
were qualified as pre-eclamptic and included in the study
group. Blood samples from the patients with pre-eclampsia
were taken on admission to the hospital before antihyper-
tensive treatment had been given. In most cases, the pa-
tients were admitted to the hospital to receive hypertension
treatment. Some of them showed intrauterine growth re-
tardation (IUGR). The average blood collection time for
pre-eclampsia was 33.02 ± 3.45 weeks of gestation. All pre-
eclamptic patients were diagnosed in the third trimester of
pregnancy. None of the pre-eclamptic patients was affect-
ed by preexisting clinical disorders, such as chronic hyper-
tension, diabetes, overweight/obesity, renal diseases or con-
nective tissue diseases before pregnancy and none of the
pregnancies was complicated by preterm labor or chorio-
amnionitis. The other pregnant patient group comprised 52
healthy women with physiological pregnancy. Blood sam-
ples from healthy pregnant women were collected through-
out their pregnancies (in the first, second and third trimes-
ters) to minimize patient variance. Blood collection time
was as follows: I trimester — 8.47 ± 1.99 weeks of gesta-
tion; II trimester — 19.37 ± 2.93 weeks of gestation;
III trimester — 33.41 ± 3.33 weeks of gestation. All preg-
nancies in the study and control groups were singleton. The
clinical characteristics of patients with pre-eclampsia and
healthy women in the third trimester of uncomplicated preg-
nancy are given in Table 1.
There were also 24 healthy non-pregnant women with
a history of successful pregnancies included in the study.
Non-pregnant women (age 19–34) did not take any contra-
ceptive pills. They had regular, biphasic (ovulatory) cycles.
Blood samples from non-pregnant women were collected
on days 20–23 of the menstrual cycle. The menstrual cycles
of women were monitored. The pre-ovulatory LH surge,
the rise in the basal body temperature (BBT), and the chang-
es in cervical mucus were taken into account to assess the
ovarian cycle. For non-pregnant women, the pre-ovulatory
LH surge was estimated with the use of commercially avail-
able ovulation tests measuring the level of LH in urine sam-
ples (Ovulation test, Laboratoire SBH, Strasbourg, France).
Complete medical, surgical, and social history was obtained
from all women.
Ethical issues. The study design was accepted by the local
Ethics Committee. Informed consent from the study sub-
jects for peripheral blood sampling was obtained.
Blood collection. Five milliliters of blood were taken from
each patient and every woman from the control group by
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venipuncture in sterile conditions and collected in sterile
tubes. Blood samples were centrifuged for 15 min at 600 g
at 4°C. Serum was separated from the cells within 15 min-
utes after collection of blood. Next, serum was frozen at
–80°C until assayed. Duration of storage before measure-
ment was up to seven months.
The measurements of sera HLA-G concentrations. The con-
centrations of sHLA-G protein in sera samples were deter-
mined by a specific double monoclonal sandwich enzyme
immunoassay ELISA technique (BioVendor Laboratory
Medicine, Heidelberg, Germany) according to the manu-
facturer’s instructions. It measured shedded HLA-G1 and
HLA-G5 isoforms (14). The analytical sensitivity was 1 U/ml.
The range of the calibration curve was 3.91–125 Units/ml.
The intra-assay coefficient of variation was 5.2–10%. The
inter-assay coefficient of variation was 5.5–6.2%. The neg-
ative and positive controls used in the study were provided
by the manufacturer. Standard and analyzed samples were
coated with mouse anti-human sHLA-G monoclonal anti-
body and put into the microplate wells. The analyzed sam-
ples were tested in duplicate. After one-hour incubation at
room temperature, sHLA-G protein linked with monoclonal
antibody. An antibody overflow was washed out three times
with Washing Buffer. Washing Buffer was made from Wash
Solution Concentrate. The content of Wash Solution Con-
centrate is PBS pH 7.4 with detergent — 0.05% Tween-20.
Washing Buffer is a solution of 100 ml of Wash Solution
Concentrate and 400 ml of distilled water. The next step
was to incubate the plate for one hour at room temperature
with Conjugate Solution (mouse monoclonal anti-human
b2-microglobulin antibody, Horseradish Peroxidase Conju-
gate). The subsequent step was to wash out the plate three
times with the Washing Buffer to remove unconnected an-
tibody. Next, the enzyme substrate solution was added and
the color reaction was performed. The plate was incubated
for 15 minutes. The color intensity depended on the con-
centrations of sHLA-G molecule in the analyzed samples.
Finally, the stop solution (0.2 M H2SO4) was added and the
development of color reaction was inhibited. The absor-
bance was measured at wavelength l = 450 nm. Standard
curve was used to establish the concentrations of sHLA-G
protein in analyzed samples.
Statistic analysis. The statistical differences in the group of
healthy pregnant women between the first, second and third
trimesters of pregnancy were estimated using ANOVA test.
The statistical differences between the group of patients with
pre-eclampsia and healthy third trimester pregnant women
were estimated with the use of Mann–Whitney U test. The
results were presented as mean and standard deviation of
the data. Differences at p < 0.05 were considered as statis-
tically significant. Statistica 7.1 (Krakow, Poland) software
was applied to statistical analysis.
Results
The concentrations of sHLA-G molecule in sera of
patients with pre-eclampsia were significantly lower
than in sera of healthy third trimester pregnant wom-
en (p < 0.01).
The concentrations of sHLA-G molecule in sera
of healthy first trimester pregnant women were signif-
icantly higher than in healthy non-pregnant women
(p < 0.005). Similarly, the concentrations of sHLA-G
in sera of healthy second and third trimester women
Table 1. Clinical characteristics of patients with pre-eclampsia (study group) and healthy women in the third trimester of
uncomplicated pregnancy (control group)
Study group Control group Significance
Mean ± SD Mean ± SD (p)
(n = 35) (n = 52)
Maternal age 28.43 ± 4.67 28.07± 4.83 NS
Gravidity 1.79 ± 1.66 1.72± 0.91 NS
Parity 1.56 ± 0.83 1.39± 0.69 NS
Time of blood collection (weeks of gestation) 32.62 ± 4.17 33.97± 3.48 NS
Systolic pressure [mm Hg] 152.45 ± 13.94 113.48± 19.17 < 0.01
Diastolic pressure [mm Hg] 98.34 ± 4.89 74.77± 6.79 < 0.05
Proteinuria [g/24 hours] 1.43 ± 0.85 Absent –
Uric acid [mg/dl] 5.85 ± 1.43 3.42 ± 1.25 < 0.01
Creatinine [mg/dl] 1.1 ± 0.3 0.7 ± 0.2 < 0.05
Bilirubin [mg/dl] 0.7 ± 0.3 0.5 ± 0.2 NS
Fibrinogen [µg/l] 615.35 ± 120.85 495.05 ± 0.15 NS
Fetal weight [g] 2,580 ± 615 3,175 ± 352 < 0.05
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were significantly higher than in healthy non-preg-
nant women (p < 0.0001 and p < 0.005 respectively).
Furthermore, the serum concentrations of sHLA-G
in pre-eclamptic patients were significantly higher
than in healthy non-pregnant women (p < 0.01).
The concentrations of sHLA-G molecule in the sera
of women in the second trimester of physiological preg-
nancy were significantly higher than in the first and
third trimesters (p < 0.01). There were no statistically
significant differences between the sera concentrations
of sHLA-G molecule in the first and the third trimes-
ters of physiological pregnancy. There were negative
correlations between the levels of uric acid and the con-
centrations of sHLA-G in sera of patients with pre-
eclampsia, as well as the levels of creatinine and the
concentrations of sHLA-G in sera of patients with pre-
eclampsia (p < 0.05). The results of sHLA-G concen-
trations in sera of patients with pre-eclampsia, as well
as healthy pregnant women in the first, second and third
trimesters of pregnancy and healthy non-pregnant
women, are presented in Table 2.
Discussion
In pregnancy, the fetus modulates the maternal im-
mune system activity so as not to be rejected from
the host organism. It is possible because of the pla-
centa barrier as well as immunomodulatory alter-
ations. It has been suggested that the failure of ma-
ternal immunomodulation may be the cause of some
complications of pregnancy, e.g. pre-eclampsia, in-
trauterine growth retardation (IUGR) and placental
abruption [3, 4, 8].
It has been found that sHLA-G molecule is re-
leased by endovascular trophoblast cells invading
maternal spiral arteries. This could explain its pres-
ence in the maternal blood circulation. The antigen
HLA-G may play a specific immunosuppressive role
during pregnancy [10, 12, 14, 20, 21]. Although the
mechanisms of the immune system modulation by this
molecule remain unclear, studies have shown that
sHLA-G is necessary for a local tolerance induction at
the fetal–maternal interface, transplantation toler-
ance and probably tumor progression [11, 15, 23–25].
It has also been revealed that mixed lymphocyte cul-
tures, mainly cytotoxic T lymphocytes, were inhibited
by sHLA-G molecule. Moreover, Fournel et al. demon-
strated that binding of sHLA-G induces apoptotic CD8+
T-cell through the Fas/FasL pathway [27]. It has also
been noted that sHLA-G molecules are produced by
medullary epithelial thymus cells. This might suggest
that central presentation opens the possibility of a thymic
HLA-G restricted T cells development [19, 26]. There
is a possibility that killing T cells requires high concen-
trations of sHLA-G protein that would be expected at
the maternal–fetal interface [29, 30]. sHLAG1/G5 has
also been identified in supernatant of the embryo’s cul-
ture as a marker for successful implantation [28].
In our study, we found higher concentrations of
sHLA-G molecule in sera of pregnant women in all
trimesters of pregnancy compared to healthy non-
-pregnant women. Furthermore, we observed that the
concentrations of sHLA-G molecule increased in the
second trimester compared to the first trimester of
physiological pregnancy and then decreased in the
third trimester of pregnancy compared to the second
trimester to levels similar to those in the first trimes-
ter of physiological pregnancy. The concentrations of
sHLA-G in sera of pregnant women with pre-eclamp-
sia were significantly lower compared to the third tri-
mester of physiological pregnancy.
Yie et al. noticed significantly higher levels of
sHLA-G molecule during pregnancy in comparison
with non-pregnant women. They observed a decreas-
ing tendency during the normal course of pregnancy.
They revealed that the levels of sHLA-G molecule
decreased in serum during the third trimester in wom-
en who had symptoms of severe PE [28]. Another
study showed that sHLA-G concentrations were sig-
nificantly higher in each of the three trimesters of
Table 2. Concentrations of sHLA-G molecule (Units/ml) in sera of healthy non-pregnant women, healthy pregnant
women in the first, second and third trimesters of physiological pregnancy, and patients with pregnancy complicated by
pre-eclampsia
Number of patients Mean ± SD Statistical significance
(n) [U/ml] (p)
Non-pregnant women 24 10.54 ± 7.11 p < 0.01
I trimester women 52 49.14 ± 31.02 p < 0.001
II trimester women 52 91.49 ± 41.58 p < 0.01
III trimester women 52 63.31 ± 32.63 p < 0.005
Patients with pre-eclampsia 35 33.74 ± 28.30 p < 0.01
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pregnancy than in non-pregnant women [23]. Simi-
larly to our results, Hackmon et al. demonstrated sig-
nificantly lower levels of sHLA-G molecule during
the third trimester of pregnancy in patients suffering
from severe pre-eclampsia [19, 21]. It has also been
reported that there is decreased expression of HLA-G
antigen in placenta of women with pre-eclampsia com-
pared to normal pregnancies [22].
In the study by Steinborn et al., the levels of
sHLA-G1/G5 strongly increased during the first trimes-
ter of normal pregnancy compared to non-pregnant
women, and then decreased continuously toward term.
The pregnant women with significantly decreased
sHLA-G1/G5 levels in the second trimester had an
increased risk of developing pre-eclampsia and/or
IUGR during the further course of pregnancy. How-
ever, in the third trimester, sHLA-G1/G5 levels in
affected women did not deviate significantly from
those of non-affected women. The authors conclud-
ed that for the identification of women with an in-
creased risk of IUGR and/or pre-eclampsia, the mea-
surement of sHLA-G1/G5 plasma levels may be
a powerful new tool in prenatal diagnostics [21].
It seems possible that more elevated concentra-
tions of sHLA-G in the sera of healthy pregnant wom-
en in the second trimester of normal pregnancy may
be associated with the disappearance of trophoblast
plugs in maternal spiral arteries [30]. On the other
hand, the increased risk of pre-eclampsia and/or
IUGR in women who had decreased levels of sHLA-
G1/G5 in the second trimester may be the effect of
disturbances in the process of disappearance of tro-
phoblast plugs in the spiral arteries.
The expressions of HLA-G antigen are up-regu-
lated at the time when trophoblast differentiates to
an invasive pathway. Furthermore, a soluble form of
HLA-G protein derived from an alternatively spliced
form of mRNA may participate in the vascular re-
modeling of maternal spiral arteries during pregnan-
cy through an interaction with CD160. In addition to
this, sHLA-G molecule modulates the secretion of
cytokines, induces immunotolerance, influences NK
cell function, and controls the invasion of trophoblast
during pregnancy [30–36]. It is now becoming increas-
ingly clear that it may influence pregnancy outcome
at several levels. In normal pregnancy, it appears that
the major function of NK cells is to provide benefit
by secreting a number of cytokines, chemokines and
angiogenic factors rather than to exert a cytotoxic
activity [37–39]. It has been found that sHLA-G binds
KIR2DL4 receptor which triggers secretion of proan-
giogenic factors that control vascular uterine remod-
eling [40, 41].
It is known that during human pregnancy the phys-
iological invasion of cytotrophoblast inside the uter-
ine wall consist of two phases. The first step of the
invasion takes place at the beginning of the pregnan-
cy after the process of fertilization. After a long pause,
which lasts about 6–8 weeks, there is a second very
deep physiological invasion of the cytotrophoblast at
the beginning of the second trimester, around 14–16
weeks of gestation. The second invasion of the cy-
totrophoblast to spiral arteries is completed at 18–20
weeks of gestation [3, 4].
The differences between the results of our study
and those of other authors could result from differ-
ent assay forms, different patient group composition,
and different time point of collection. The ELISA test
used in our study measured sHLA-G1 and HLA-G5
protein concentrations which are the main isoforms
presented in serum. The secondary monoclonal anti-
body used was directed against human b2-microglob-
ulin. The use of this antibody excludes the detection of
sHLA-G free heavy chains. This test does not discrim-
inate the different sHLA-G isoforms — sHLA-G6 [41].
Furthermore, a large number of patients with pre-
eclampsia and healthy pregnant women were included
in our study.
The results of our study suggest that normal phys-
iological pregnancy is associated with elevated sera
concentrations of sHLA-G molecule. It seems possi-
ble that elevated concentrations of sHLA-G molecule
during mid-gestation are associated with the process
of disappearance of trophoblast plugs in the spiral
arteries during the second phase of a physiological
invasion of extravillous cytotrophoblast which is com-
pleted at 18–20 weeks of gestation. Furthermore, the
results can suggest the role of the decreased sera con-
centrations of sHLA-G in the pathogenesis of pre-
eclampsia.
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